On this page
POU3F4
POU class 3 homeobox 4
POU3F4 is located on the long (q) arm of chromosome X, at band Xq21.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome X in the library →Available at Jeen Health
Clinical tests that include this
Overview
POU3F4 belongs to a family of developmental transcription factors that help determine cell identity in the central nervous system and sensory organs. The protein plays a critical role in the proper formation of structures within the middle and inner ear during foetal development. Changes in this gene represent an important genetic cause of hearing impairment that is not accompanied by other clinical features, a presentation known as nonsyndromic hearing loss. Because POU3F4 is located on the X chromosome, the inheritance pattern and clinical expression differ between males and females.
Understanding how this gene contributes to auditory development has implications for genetic counselling and family planning. Identification of pathogenic POU3F4 variants allows families to understand the cause of hearing loss and to anticipate patterns of inheritance in future generations.
What the gene does
The POU3F4 protein functions as a transcription factor, meaning it binds to specific DNA sequences and controls whether other genes are switched on or off. This regulatory activity is particularly important during embryonic development, when precise timing of gene expression determines how tissues and organs form. Evidence suggests the protein is active in specific regions of the developing brain as well as in structures that will become the middle and inner ear.
The protein's ability to bind DNA depends on two specialised regions within its structure: the POU-specific domain and the POU homeodomain. These regions work together to recognise particular DNA sequences near genes involved in auditory system development. By controlling the activity of these downstream genes, POU3F4 helps coordinate the complex process of ear formation. Researchers continue to investigate which specific genes are regulated by this transcription factor and how disruption of these regulatory networks leads to hearing impairment.
Video: Genetics 101
Chromosome location
POU3F4 is located on the long arm of the X chromosome at position Xq21.1. This chromosomal location places the gene within a region that escapes X-inactivation in some contexts, though the clinical implications of this are still being investigated. The X-linked position means that males, who have only one X chromosome, are typically more severely affected by pathogenic variants than females, who have two X chromosomes and may benefit from expression of the normal copy.
Protein structure
The POU3F4 protein comprises 361 amino acids and contains the characteristic domain architecture of the POU transcription factor family. The POU-specific domain spans amino acids 186 to 260, whilst the homeobox DNA-binding domain occupies positions 278 to 337. These two domains work in tandem to achieve sequence-specific DNA recognition and binding. The protein also contains disordered regions at amino acids 99 to 131 and 144 to 192, which may provide flexibility for protein-protein interactions or regulatory modifications. The structural organisation of these domains is essential for the protein's function in controlling gene expression during development.
Key variants
Pathogenic variants in POU3F4 cause a form of X-linked nonsyndromic hearing loss designated DFNX2, sometimes referred to as Nance deafness. These variants may include changes within the gene's coding sequence that alter the protein structure, or deletions and rearrangements that affect regulatory regions controlling when and where the gene is expressed. Because this gene is located on the X chromosome, males with a single pathogenic variant typically experience more pronounced hearing loss than heterozygous females. The specific effect of a variant often depends on whether it disrupts the DNA-binding domains or affects the gene's expression level.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Variants in POU3F4 are associated with X-linked nonsyndromic hearing loss, meaning affected individuals experience hearing impairment without other systemic features or developmental concerns. DFNX2 represents the most common form of X-linked hearing loss, accounting for roughly half of cases with this inheritance pattern. The hearing loss associated with POU3F4 variants is typically congenital or appears in early childhood, and may be accompanied by characteristic findings on temporal bone imaging. Because the condition is nonsyndromic, cognitive development and other organ systems remain unaffected.
No disease links recorded for this gene in our reference set.
UK clinical status
POU3F4 is included on the NHS Genomic Medicine Service Monogenic hearing loss panel with a green classification at version R67, indicating strong evidence supporting its role in inherited hearing impairment. This panel guides genetic testing for individuals and families affected by hereditary hearing loss within the NHS. Inclusion on this panel means that testing for POU3F4 variants may be available through NHS clinical genetics services for eligible patients meeting referral criteria.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
Why does POU3F4-related hearing loss affect males more severely than females?
POU3F4 is located on the X chromosome, and males have only one X chromosome whilst females have two. Males with a pathogenic variant lack a second copy to compensate, typically resulting in more pronounced hearing loss. Females with one pathogenic variant often have milder features or normal hearing because their second X chromosome carries a functional copy of the gene.
Is POU3F4-related hearing loss present from birth?
Hearing loss associated with POU3F4 variants is typically congenital, meaning it is present at birth, or appears in early childhood. The severity and age of onset can vary between individuals, even within the same family, depending on the specific variant and other genetic or environmental factors.
Can genetic testing for POU3F4 help guide treatment decisions?
Genetic testing can confirm the underlying cause of hearing loss and provide information for family planning, but it does not typically change immediate clinical management. Identification of a POU3F4 variant may, however, inform decisions about hearing aids, cochlear implantation candidacy, and monitoring, as some studies suggest particular imaging findings may influence surgical planning. Families should discuss findings with their audiology and genetics teams.